An Open Label Randomised Controlled Clinical Study to Evaluate the Efficacy of Virechana followed by Bruhat Panchamoola Kashaya in the Management of Dyslipidemia

Dyslipidemia is a disorder of lipoprotein metabolism, which can include overproduction or deficiency of lipoproteins or both. The disorder can manifest as an elevation of plasma cholesterol, triglycerides, or both, or a low HDL level or all three together that contributes to the development of atherosclerosis.

The prevalence of Dyslipidemia across the nation has been reported as; 24.0% of hypercholesterolemia, 20.9% of high LDL-cholesterol, 66.9% low HDL-cholesterol and 32.1% of hypertriglyceridemia. Cardiovascular disease is the most significant complication of Dyslipidemia owing to more than 4 million deaths each year, worldwide.

The management protocol for Dyslipidemia includes lifestyle modifications, diet, exercise and administration of statins in various intensities. Statin therapy is also used in primary and secondary prevention of the disease. It is added with two other classes of medications aimed at inhibiting the absorption of cholesterol and decreasing LDL-C levels which has in turn shown to decrease cardiovascular outcomes.

Many Ayurvedic formulations have been proven to have anti-dyslipidemic activity. There remains a scope for research in this field owing to the prevalence of the disease. Therefore, Bruhat Panchamoola Kasha has been chosen as the trial drug for the present study. Triphala Kasha, a proven drug for Dyslipidemia, is taken as the control drug.